Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled, Single-blind, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics After Single and Multiple Dose of Elinzanetant in Japanese Healthy Female Adult Participants

NCT04981431 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT04981431
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04981431 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled, Single-blind, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics After Single and Multiple Dose of Elinzanetant in Japanese Healthy Female Adult Participants
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
August 11, 2021
Completion date
March 13, 2022
Enrollment
62 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

vasomotor symptoms as a sex hormone-dependent disorder in women and men